RSS Larimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's Ataxia

Currently reading:
 RSS Larimar Reports Positive Initial Data From Long-term OLE Study Of Nomlabofusp In Friedreich's Ataxia

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,209
Likes
1,916
Credits
32,769©
Cash
0$
Larimar Therapeutics, Inc. (LRMR) announced promising preliminary results on Monday from the long-term open-label extension (OLE) study of nomlabofusp, a treatment being tested in individuals with Friedreich's Ataxia.

Friedreich's Ataxia is an inherited disorder characterized by progressive degeneration of the nervous system. The OLE study results indicated that nomlabofusp treatment led to an increase in frataxin levels among participants. Given that a deficiency in frataxin is the underlying cause of Friedreich's Ataxia, boosting these levels could potentially decelerate the disease's progression.

The company reiterated its schedule to launch a registrational study for nomlabofusp by mid-2025 and plans to file a Biologics License Application (BLA) in the latter half of 2025.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom